人类白细胞抗原E联合高危型人乳头瘤病毒检测在高级别鳞状上皮内病变和宫颈鳞癌中的诊断价值

doi:10.3969/j.issn.1671-7171.2020.10.030

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To investigate the diagnostic value of combined detection of human leukocyte antigen E (HLA-E) and high-risk human papillomavirus (HR-HPV) in high-grade squamous intraepithelial lesion (HSIL) and cervical squamous cell carcinoma.【Methods】 Forty patients with low-grade squamous intraepithelial lesions (LSIL, LSIL group), 40 patients with HSIL (HSIL group), and 40 patients with cervical squamous cell carcinoma (cervical squamous cell carcinoma group) were selected from January 1, 2017 to April 30, 2019 in our hospital. Forty patients with chronic cervicitis who were treated at the same time were selected as the control group. All patients received HR-HPV and liquid-based cytology (TCT). The expression of HLA-E was detected by immunohistochemistry. The diagnostic value of HLA-E combined with HR-HPV and TCT combined with HR-HPV in HSIL and cervical squamous cell carcinoma were observed. 【Results】 The positive rate of HLA-E expression in cervical squamous cell carcinoma was higher than that in the HSIL group, the LSIL group and the control group (P<0.05). The positive rate of HLA-E expression in the HSIL group was higher than that in the LSIL group and the control group (P<0.05). There was no significant difference in the positive rate of HLA-E expression between the control group and the control group (P>0.05). The positive rate of HR-HPV in the cervical squamous cell carcinoma and HSIL group was higher than that in the LSIL group and the control group (P<0.05). The positive rate of the HR-HPV in the LSIL group was higher than that in the control group (P<0.05). There was no significant difference in the positive rate of HR-HPV between the cervical squamous cell carcinoma group and the HSIL group (P>0.05). The accuracy of TCT in the diagnosis of chronic cervicitis, LSIL, HSIL, and cervical squamous cell carcinoma was 35.0%, 42.5%, 40.0%, and 52.5%, respectively. The ROC curve showed that the AUC of HLA-E combined with HR-HPV in the diagnosis of HSIL and cervical squamous cell carcinoma was 0.737, and the specificity was 68.1% and 70.8%.There was no significant difference in AUC between TCT combined with HR-HPV and HLA-E combined with HR-HPV (P>0.05). 【Conclusion】 HLA-E is highly expressed in HSIL and cervical squamous cell carcinoma. HLA-E combined with HR-HPV is of high value in the diagnosis of HSIL and cervical squamous cell carcinoma, which is equivalent to TCT combined with HR-HPV.

Key words： Uterine Cervical Neoplasms/DI Carcinoma Squamous Cell/DI Papillomaviridae HLA Antigens

Received: 25 September 2019

PACS:

R713.4

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	MAO Shuang
	TAN Ye

Cite this article:

MAO Shuang,TAN Ye. Diagnostic Value of Combined Detection of Human Leukocyte Antigen (HLA-E) and High-risk Human Papillomavirus in High-grade Squamous Intraepithelial Lesions and Cervical Squamous Cell Carcinoma[J]. JOURNAL OF CLINICAL RESEARCH, 2020, 37(10): 1538-1541.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2020.10.030 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2020/V37/I10/1538

[1] Hillemanns P, Soergel P, Hertel H, et al. Epidemiology and Early Detection of Cervical Cancer[J].Oncol Res Treat,2016,39(9):501-506.
[2] El-Zein M, Richardson L, Franco EL. Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none[J].J Clin Virol,2016,76 (Suppl 1):S62-S68.
[3] Luttmer R, De Strooper LM, Steenbergen RD, et al. Management of high-risk HPV-positive women for detection of cervical (pre)cancer[J].Expert Rev Mol Diagn,2016,16(9):961-974.
[4] Seliger B, Jasinski-Bergner S, Quandt D, et al. HLA-E expression and its clinical relevance in human renal cell carcinoma[J].Oncotarget,2016,7(41):67360-67372.
[5] 江恩利,谭寒星,冉光伟, 等.老年宫颈癌组织中人类白细胞抗原-E蛋白的表达及与临床病理特征的关系[J].中国老年学杂志,2017,37(15):3779-3781.
[6] 李丽娟,张秋菊,樊素珍.TCT联合HR-HPV检测在宫颈癌及癌前病变早期筛查中的应用价值[J].癌症进展,2019,17(21):2569-2571.
[7] 张慧琦,陈群.宫颈癌前病变和宫颈癌高危型HPV分布特点[J].医学临床研究,2019,36(9):1841-1843.
[8] 黄江梅,肖芳,赵敏, 等.GDF-15miRNA在宫颈癌患者血清中的表达及其意义[J].医学临床研究,2019,36(9):1671-1673.
[9] Babay W, Ben YH, Boujelbene N, et al. Clinicopathologic significance of HLA-G and HLA-E molecules in Tunisian patients with ovarian carcinoma[J].Hum Immunol,2018,79(6):463-470.
[10] 王遥,崔国英,王飞, 等.人类白细胞抗原-E 在宫颈癌中的表达及意义[J].山东大学学报(医学版),2016,54(9):59-63.
[11] Spaans VM, Peters AA, Fleuren GJ, et al. HLA-E expression in cervical adenocarcinomas: association with improved long-term survival[J].J Transl Med,2012,10:184.
[12] 张春华,宋晓玲,康凌, 等.中晚期宫颈癌HPV感染阳性患者放疗随访期HPV及TCT变化及相关性研究[J].中华医院感染学杂志,2018,28(16):2522-2525.